100 related articles for article (PubMed ID: 26215797)
1. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
Levine JE
Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
Dvorak CC; Callard E; Agarwal R
Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
[No Abstract] [Full Text] [Related]
4. Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hamilton BK; Kalaycio M
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1869-70. PubMed ID: 25065905
[No Abstract] [Full Text] [Related]
5. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
Busca A; Locatelli F; Marmont F; Audisio E; Falda M
Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
7. Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD).
Castagna L
Haematologica; 2003 Aug; 88(8):ELT28; author reply ELT29. PubMed ID: 12935991
[No Abstract] [Full Text] [Related]
8. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hattori K; Doki N; Kurosawa S; Hino Y; Yamamoto K; Sakaguchi M; Harada K; Ikegawa S; Shingai N; Senoo Y; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Ann Hematol; 2017 Feb; 96(2):319-321. PubMed ID: 27766393
[No Abstract] [Full Text] [Related]
10. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
12. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
13. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
[TBL] [Abstract][Full Text] [Related]
14. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation.
Menillo SA; Goldberg SL; McKiernan P; Pecora AL
Bone Marrow Transplant; 2001 Oct; 28(8):807-8. PubMed ID: 11781637
[No Abstract] [Full Text] [Related]
15. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients.
Kiehl MG; Schäfer-Eckart K; Kröger M; Bornhäuser M; Basara N; Blau IW; Kienast J; Fauser AA; Ehninger G; Armstrong VW; Shipkova M
Transplant Proc; 2002 Nov; 34(7):2922-4. PubMed ID: 12431658
[No Abstract] [Full Text] [Related]
17. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
18. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
20. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy.
Grundmann-Kollmann M; Behrens S; Gruss C; Gottlöber P; Peter RU; Kerscher M
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):134-6. PubMed ID: 10607334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
